Full text is available at the source.
Abstract
The increasing rates of type 2 diabetes mellitus (T2DM) and obesity are driving the search for more effective therapeutic methods.
- Current treatment options include monoagonists such as liraglutide, dulaglutide, and semaglutide.
- Dual incretin receptor agonists like tirzepatide are also being explored for their potential benefits.
- New classes of triple- and tetra-agonists of gastrointestinal hormones are under development.
- These advancements may lead to more effective complex treatments for both T2DM and obesity.
Simplified